Moody’s: Fasten Your Seat Belts, But Not for AI
Moody’s ratings business faces potential deceleration, while AI-related debt issuance and anti-data-center politics pose less risk than investors fear.
Moody’s ratings business faces potential deceleration, while AI-related debt issuance and anti-data-center politics pose less risk than investors fear.
@walnutavevalue Interesting, thanks. Was not aware of $BBW's licensing angle
What an interesting question... is there a repeatable "tough industry" playbook which creates value over time? $DDS is a share cannibal with an ugly looking revenue picture (no growth from 1998-2026 / declining) https://t.co/v8YKS28dN9 https://t.co/7e3nlBYuad
Small Bay Industrial investors will do everything in SoCal instead of buying $REXR If you’re looking to deploy more than 7 figures in SoCal smallbay industrial, $REXR is much cheaper and literally selling some warehouse to the aggressive buyers Using proceeds to buy back shares further boosting intrinsic value Crazy public arbitrage of private market value DM open if you actually want to get more than 7 figures of exposure to SoCal warehouse
Just got a Pokemon rip offer in the Dunkin Donuts app. $GME is a sleeping giant. https://t.co/8QDb89DOJu
Dillard's $DDS is an interesting case study on shareholder value creation in the face of enormous industry headwinds. My question - is there a repeatable "tough industry" playbook here, or were there one-off factors that allowed it to occur? https://t.co/SkggeTE4cY
Softening Colombian Peso, falling interest rates, tariffs going away. Perfect set-up brewing. $TGLS https://t.co/3UHXULRh5V https://t.co/FkvlubmoV8
Ouster grew Q3 revenue 50% to $59.3 million, shipped 27,000 sensors and guided Q4 revenue to $61 million to $64 million while posting a…
Floor & Decor’s 3Q26 sales rose 3% while comparable sales fell 1.4%; it cut 2027 openings to 10-15 as high mortgage rates pressure…
Floor & Decor's 3Q26 sales rose 3% while comparable sales fell 1.4%; it slowed 2027 openings to 10-15 as high mortgage rates pressure…
Kimberly-Clark’s Kenvue merger targets $1.9 billion in synergies by 2029, supporting roughly 6% long-term EPS growth and continued dividend…
Blue Dolphin’s 15,000-barrel-per-day Texas refinery earned $2.18 per share in first-half 2026 as diesel shortages widened crack spreads,…
Park Hotels & Resorts grew Q3 occupancy and RevPAR as renovations supported group and leisure demand, while leverage, Hawaii exposure and…
Procore CFO Rachel Pyles discusses accelerating growth and economies of scale after an upbeat third-quarter report.
Diageo’s first quarter under CEO Dave Lewis showed modest price changes and regional growth outside North America, supporting a turnaround…
Tower Semiconductor reported $526 million in quarterly revenue and extended photonics contracts through 2029, while its low-loss silicon…
Applied Materials trades at 17.93x forward earnings, with analysts forecasting more than 45% EPS growth through 2028 and a net-cash balance…
EUXTF · long Euronext has evolved from a regional cash-equities exchange into a pan-European market-infrastructure platform after a decade of technology…
Adobe investment case summary.
Deere raised net income and cash flow guidance despite a 10% Production and Precision Ag sales decline, as construction and small-ag…
IRhythm’s ZEUS clearance cuts clinician review time 50%, targeting $100 million in five-year savings as cardiac monitoring margins expand…
Stabilis Solutions lost its Galveston LNG offtake anchor, revenue fell 36% in 1H’26, and limited liquidity leaves its data-center power…
Real Brokerage’s RE/MAX acquisition would triple its agent count, diversify revenue with franchise fees and expand share during a weak U.S.
Corcept Therapeutics expects Lifyorli and Korlym to support 44% revenue growth, while FDA and European decisions on relacorilant could…
El Al trades near 2x EBITDA after wartime near-monopoly profits, with $1.3 billion of net cash and owned aircraft weighed against…
Bank of America’s BAC.PR.B yields just over 6% near par, while discounted lower-coupon series such as BAC.PR.P offer better value despite…
Moderna's Phase 3 intismeran autogene trial met its recurrence-free survival endpoint in adjuvant melanoma, supporting an asymmetric…
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.